BioMarin Files BLA For Gene Therapy To Treat Hemophilia A
Zacks Investment Research | Dec 23, 2019 09:30PM ET
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that it has submitted a biologics license application (“BLA”) to the FDA seeking approval for valoctocogene roxaparvovec, an investigational gene therapy, developed for treating adult patients with severe hemophilia A.
The company anticipates that the review of the BLA will be initiated by the regulatory authority in February 2020. The FDA will provide an update on whether it will accept the BLA or not after completing the filing review.
The marketing application was based on industry ’s increase of 9.1%.
We remind investors that BioMarin was conducting two separate phase III studies, namely GENEr8–1 (6e13 vg/kg dose) and GENEr8–2 (4e13 vg/kg dose) on valoctocogene roxaparvovec for the treatment of patients without the pre-existing AAV5 antibodies.
However, the company stopped developing 4e13 vg/kg dose (GENEr8–2 study) of valoctocogene roxaparvovec due to patient preference for the 6e13 vg/kg dose. The GENEr8-1 study, however, continued to enroll for achieving its planned completion target of 130 total patients.
In a separate press release, BioMarin announced that its marketing authorization application seeking approval for valoctocogene roxaparvovec as a treatment for severe hemophilia A has been validated by the European Medicines Agency. The review of the regulatory application will start in January 2020 under accelerated assessment.
Hemophilia A is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Despite being prescribed the current standard of care medicines, patients with severe hemophilia A persistently experience painful bleeds, thereby creating significant need for medicines that can improve patients' quality of life. Several companies are developing gene therapy products to treat severe hemophilia A.
Notably, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) and partner Pfizer, Inc. (NYSE:PFE) are evaluating their gene therapy candidate SB-525 in a phase III study for addressing patients with severe hemophilia A. Other companies developing gene therapy candidates to treat hemophilia A include Roche and uniQure (NASDAQ:QURE) .
BioMarin Pharmaceutical Inc. Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.